30 April 2009
Simon Varcoe
Sanofi-Aventis has discontinued, halted or returned the rights to 14 R&D projects currently in its pipeline as its CEO Chris Viehbacher continues to overhaul the business.
The company's net sales increased by 3% to €7.11 billion as it benefited from a 2.7 point positive currency...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Teva to buy Cephalon for $6.8 billion, topping Valeant's unsolicited bid
- Sanofi results: Genzyme doesn't paper over cracks, as emerging markets top US and EU
- Merck Serono ditches cladribine, leaving MS franchise exposed
- US FDA denies Teva's plea to reject generic Copaxone apps
EVENTS
Today
London
28 February 2012
Pestana Chelsea Bridge Hotel London
04 March 2012
The Marriott World Center, Orlando, Florida
JOB OF THE WEEK
Promote your vacancy here
